EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis

Mi Yang, Xingxing Cui, Di Kong, Xincheng Huang, Guocheng Zhao, Xiuying Li, Huachang Zhao, Liju Liu, Fei Yan, Yan Yang, Zezhi Li

European Archives of Psychiatry and Clinical Neuroscience · 2025

DOI: 10.1007/s00406-024-01935-4 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, 2025. Verfasst von Mi Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, The Fourth People's Hospital of Chengdu, No. 8 Huli-West 1st-Alley, Jin-Niu District, Chengdu, 610036, China. 565136170@qq.…. Hauptthemen laut MEDLINE: Schizophrenia, Probiotics, Gastrointestinal Microbiome, Lactobacillus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Medical Association, Chengdu Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The modulation of gut microbiota through probiotics holds promise as a novel avenue for schizophrenia treatment. This study aims to analyze probiotic complementary therapy on individuals with schizophrenia systematically, to investigate probiotic efficacy, potential mechanisms, and implications for clinical practice. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched in Medline, Web of Science, Embase, ClinicalTrials.gov, CNKI, VIP, and WanFang databases using keywords ("probiotics" OR "prebiotics" OR "synbiotics" OR "Lactobacillus" OR "Bifidobacterium") AND ("schizophrenia"), focused on randomized controlled trials published before July 1, 2023. Among the identified studies, 8 randomized controlled trials met the inclusion criteria, encompassing a total of 342 participants in the intervention group and 306 participants in the control group. Our analysis revealed a statistically significant reduction (p = 0.03) in the total Positive and Negative Syndrome Scale (PANSS) scores following probiotic treatment in individuals with schizophrenia. While no statistical significance was observed in individual subscales (P > 0.05), significant improvements were noted in insulin levels, Insulin Resistance Index (IRI), and glucose levels. Additionally, the Quantitative Insulin Sensitivity Check Index (QUICKI) demonstrated a significant increase (all P < 0.05). The probiotic intervention significantly reduced gastrointestinal discomfort among schizophrenia patients (P = 0.003). This study suggests that probiotics could hold therapeutic potential for addressing clinical symptoms, abnormal glucose metabolism, and gastrointestinal discomfort in individuals with schizophrenia. Future research should encompass comparative trials employing robust experimental designs to explore the differential effects of various probiotic strains on schizophrenia treatment to provide evidence-based therapeutic approaches. TRIAL REGISTRATION: This review protocol was pre-registered on PROSPERO (No. CRD42023455273).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaProbioticsGastrointestinal MicrobiomeLactobacillusBifidobacteriumOutcome Assessment, Health CareHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

GlucoseInsulinMeta-analysisOxidative stressProbioticsSchizophrenia

Autor:innen und Institutionen

  • Department of Psychiatry, The Fourth People's Hospital of Chengdu, No. 8 Huli-West 1st-Alley, Jin-Niu District, Chengdu, 610036, China. 565136170@qq.com.
  • The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Qingshuihe Campus: No. 2006, Xiyuan Ave, West Hi-Tech Zone, Chengdu,…
  • School of Life Science and Technology, University of Electronic Science and Technology of China, Qingshuihe Campus: No. 2006, Xiyuan Ave, West Hi-Tech Zone, Chengdu, 611731, China. 565136170@qq.com.
  • Department of Psychiatry, The Fourth People's Hospital of Chengdu, No. 8 Huli-West 1st-Alley, Jin-Niu District, Chengdu, 610036, China.
  • Psychological Research and Counseling Center, Southwest Jiaotong University, Chengdu, 610031, China.
  • Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, 510370, China. biolpsychiatry@126.com.

Förderung

  • National Natural Science Foundation of China
  • Sichuan Medical Association
  • Chengdu Municipal Health Commission
  • Science and Technology Department of Sichuan Province

Zitieren

APA

Yang, M., Cui, X., Kong, D., Huang, X., Zhao, G., Li, X., Zhao, H., Liu, L., Yan, F., Yang, Y., & Li, Z. (2025). The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01935-4

Vancouver

Yang M, Cui X, Kong D, Huang X, Zhao G, Li X, et al. The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis. European Archives of Psychiatry and Clinical Neuroscience. 2025. doi:10.1007/s00406-024-01935-4

BibTeX
@article{Yang2025,
  author = {Yang, Mi and Cui, Xingxing and Kong, Di and Huang, Xincheng and Zhao, Guocheng and Li, Xiuying and Zhao, Huachang and Liu, Liju and Yan, Fei and Yang, Yan and Li, Zezhi},
  title = {The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis},
  journal = {European Archives of Psychiatry and Clinical Neuroscience},
  year = {2025},
  doi = {10.1007/s00406-024-01935-4}
}
Kostenlos starten →